Trial Profile
A Phase IIIb Multicenter, Open-label, Single Arm Study to Evaluate the Efficacy and Safety of Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Pasireotide (Primary)
- Indications Acromegaly
- Focus Registrational; Therapeutic Use
- Acronyms SWITCH
- Sponsors Novartis; Novartis Pharmaceuticals
- 18 Mar 2019 Results presented at the 101st Annual Meeting of the Endocrine Society
- 15 Nov 2018 Status changed from active, no longer recruiting to completed.
- 22 Oct 2018 Planned End Date changed from 17 Oct 2018 to 31 Oct 2018.